[go: up one dir, main page]

AR115571A1 - Conjugados anticuerpo droga para ablación de células madre hematopoyéticas - Google Patents

Conjugados anticuerpo droga para ablación de células madre hematopoyéticas

Info

Publication number
AR115571A1
AR115571A1 ARP190101681A ARP190101681A AR115571A1 AR 115571 A1 AR115571 A1 AR 115571A1 AR P190101681 A ARP190101681 A AR P190101681A AR P190101681 A ARP190101681 A AR P190101681A AR 115571 A1 AR115571 A1 AR 115571A1
Authority
AR
Argentina
Prior art keywords
hematopoietic stem
stem cell
antibody
antibody conjugates
drug antibody
Prior art date
Application number
ARP190101681A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR115571A1 publication Critical patent/AR115571A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente proporciona conjugados anticuerpo droga, donde un anticuerpo o fragmento de anticuerpo que específicamente se une a cKIT humano se conecta a un resto de droga, opcionalmente a través de un ligador. La presente además proporciona composiciones farmacéuticas que comprenden los conjugados anticuerpo droga; y métodos para elaborar y usar dichas composiciones farmacéuticas para ablación de células madre hematopoyéticas en el paciente que lo necesita.
ARP190101681A 2018-06-20 2019-06-18 Conjugados anticuerpo droga para ablación de células madre hematopoyéticas AR115571A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687382P 2018-06-20 2018-06-20

Publications (1)

Publication Number Publication Date
AR115571A1 true AR115571A1 (es) 2021-02-03

Family

ID=67847756

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101681A AR115571A1 (es) 2018-06-20 2019-06-18 Conjugados anticuerpo droga para ablación de células madre hematopoyéticas

Country Status (12)

Country Link
US (1) US20210228731A1 (es)
EP (1) EP3810205A2 (es)
JP (1) JP2021527429A (es)
KR (1) KR20210024542A (es)
CN (1) CN112437675A (es)
AR (1) AR115571A1 (es)
AU (1) AU2019291565A1 (es)
CA (1) CA3103939A1 (es)
IL (1) IL279440A (es)
TW (1) TW202014209A (es)
UY (1) UY38265A (es)
WO (1) WO2019244082A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999786B2 (en) * 2020-11-24 2024-06-04 Novartis Ag Anti-CD48 antibodies, antibody drug conjugates, and uses thereof
WO2023146293A1 (ko) * 2022-01-26 2023-08-03 주식회사 노벨티노빌리티 C-kit을 표적으로 하는 면역접합체
WO2025038435A1 (en) * 2023-08-11 2025-02-20 Amgen Inc. Methods of solid phase antibody conjugation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
DE69907456T2 (de) 1998-06-24 2004-03-25 Advanced Inhalation Research, Inc., Cambridge Grosse poröse partikel ausgestossen von einem inhalator
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
DK2088864T3 (en) * 2006-11-03 2017-10-02 Univ Leland Stanford Junior SELECTIVE IMMUN DEPLETATION OF ENDOGEN STEM CELL NICHES FOR INPUT
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
JP6609477B2 (ja) 2013-02-08 2019-11-20 ノバルティス アーゲー イムノコンジュゲートを調製する修飾抗体のための特定部位
KR20150131173A (ko) * 2013-03-15 2015-11-24 노파르티스 아게 항체 약물 접합체
JP6636925B2 (ja) * 2013-12-17 2020-01-29 ノバルティス アーゲー 細胞障害性ペプチドおよびその抱合体
MX2016011627A (es) 2014-03-12 2016-11-29 Novartis Ag Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
US10786578B2 (en) * 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
CA2982115A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
US20190194315A1 (en) * 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
IL263744B2 (en) * 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
JOP20190155A1 (ar) * 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم

Also Published As

Publication number Publication date
WO2019244082A2 (en) 2019-12-26
EP3810205A2 (en) 2021-04-28
US20210228731A1 (en) 2021-07-29
AU2019291565A1 (en) 2021-01-07
TW202014209A (zh) 2020-04-16
CN112437675A (zh) 2021-03-02
WO2019244082A3 (en) 2020-03-05
UY38265A (es) 2020-01-31
JP2021527429A (ja) 2021-10-14
CA3103939A1 (en) 2019-12-26
IL279440A (en) 2021-01-31
KR20210024542A (ko) 2021-03-05

Similar Documents

Publication Publication Date Title
CO2019006455A2 (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
CO2018008667A2 (es) Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso
CO2021004032A2 (es) Derivado de dinucleótido cíclico novedoso y su conjugado anticuerpo-fármaco
AR096015A1 (es) Conjugados de fármacos con anticuerpos
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
UY38700A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
CL2016002941A1 (es) Conjugación en sitio específico de fármacos enlazadores con anticuerpos y conjugados de anticuerpo-fármaco (adc) resultantes.
BR112016004242A8 (pt) Métodos para conjugação sítio-específica de anticorpos e composições
PE20170917A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
PE20090245A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
AR115571A1 (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CL2018000131A1 (es) Inmunoconjugados de il22
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
MX2020012788A (es) Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso.
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.
DOP2023000102A (es) Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
CO2022004606A2 (es) Conjugados de amatoxina y anticuerpo específicos de linfocitos b
EA201991251A1 (ru) Пептидсодержащие линкеры для конъюгатов антитело-лекарственное средство

Legal Events

Date Code Title Description
FB Suspension of granting procedure